Drugs / DAAOI-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02532686 | Oct 2014 → Jul 2016 | schizophrenia | China Medical University Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DAAOI-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02532686 ↗ |
| Action | Inhibit | “DAAOI-2, a D-amino acid oxidase (DAAO) inhibitor” NCT02532686 ↗ |
| Route | Oral | “500-2000mg/d, oral, for 6 weeks” NCT02532686 ↗ |
| Target | DAAO | “DAAOI-2, a D-amino acid oxidase (DAAO) inhibitor” NCT02532686 ↗ |